Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMO
Status:
Completed
Trial end date:
2006-01-01
Target enrollment:
Participant gender:
Summary
A 2-year, Multicenter, Open-label, Phase IIIb Extension Study to Assess Bone Mineral Density
and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women with Postmenopausal
Osteoporosis Who Sequentially Completed Clinical Studies RVE009093, RVE1996077, RVE1998080,
and RVE2001079 (NCT01249261)